Relay Therapeutics (RLAY) Income from Continuing Operations (2019 - 2026)
Relay Therapeutics (RLAY) reported Income from Continuing Operations of 73238000.0 for Q1 2026, up 4.95% year-over-year from 69780489.75 in Q1 2025, and down 33.35% quarter-over-quarter from 54920000.0 in Q4 2025.
Relay Therapeutics (RLAY) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 8 years of Income from Continuing Operations data on file, last reported at 73238000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 73238000.0, up 4.95% year-over-year; the trailing twelve-month figure through Mar 2026 was 271884000.0 (up 18.44% YoY), and the FY2025 annual result was 275703000.0, up 18.36% from the prior year.
- Income from Continuing Operations fell to 73238000.0 in Q1 2026 per RLAY's latest filing, from 54920000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 54920000.0 in Q4 2025 and troughed at 98491000.0 in Q2 2023.
- A 5-year average of 77595882.35 and a median of 76806000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations surged 60.29% in 2022, then tumbled 51.89% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 67479000.0 in 2022, then fell by 23.74% to 83496000.0 in 2023, then rose by 8.97% to 76005000.0 in 2024, then advanced by 27.74% to 54920000.0 in 2025, then slumped by 33.35% to 73238000.0 in 2026.
- Business Quant data shows RLAY's Income from Continuing Operations at 73238000.0 in Q1 2026, 54920000.0 in Q4 2025, and 73984000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Relay Therapeutics | 2.86 Bn | 2.86 Bn | - | -73.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.24 Mn |
| Dec 31, 2025 | -54.92 Mn |
| Sep 30, 2025 | -73.98 Mn |
| Jun 30, 2025 | -69.74 Mn |
| Mar 31, 2025 | -77.06 Mn |
| Dec 31, 2024 | -76.01 Mn |
| Sep 30, 2024 | -88.10 Mn |
| Jun 30, 2024 | -92.21 Mn |
| Mar 31, 2024 | -81.41 Mn |
| Dec 31, 2023 | -83.50 Mn |
| Sep 30, 2023 | -65.73 Mn |
| Jun 30, 2023 | -98.49 Mn |
| Mar 31, 2023 | -94.24 Mn |
| Dec 31, 2022 | -67.48 Mn |
| Sep 30, 2022 | -84.18 Mn |
| Jun 30, 2022 | -76.81 Mn |
| Mar 31, 2022 | -62.05 Mn |
| Dec 31, 2021 | -67.46 Mn |
| Sep 30, 2021 | -60.83 Mn |
| Jun 30, 2021 | -193.40 Mn |